Robert M. Rifkin, MD, FACP

Research Reports

Effect of Route of Bortezomib Administration on Treatment Outcomes in Previously Untreated Patients with Multiple Myeloma: A Retrospective Analysis from US Community Oncology Practices

03/08/2016

Liviu Niculescu , MD;

Robyn Harrell , MS;

Lina Asmar , PhD;

Yanyan Zhu , PhD, MPH;

Esprit Ma , MPH;

Vijayveer Bonthapally , PhD;

Robert M. Rifkin , MD, FACP;

Abstract: A phase 3 study (MMY-3021) in relapsed/refractory multiple myeloma (MM) demonstrated non-inferior efficacy and an improved systemic safety profile with subcutaneous (SC) versus intravenous (IV) bortezomib....

...

03/08/2016

Journal of Clinical Pathways

Robert Rifkin, MD, Rocky Mountain Cancer Centers

Conference Coverage

Analyzing Outpatient Administration and Step-Up Dosing of Teclistamab Among Patients With Multiple Myeloma

01/05/2024

Robert M. Rifkin , MD, FACP;

At the 65th American Society of Hematology Annual Meeting in San Diego, California, Robert M Rifkin, MD, discusses a study analyzing the outpatient administration of step-up doses of BCMA-targeting bispecific antibody teclistamab.

At the 65th American Society of...

01/05/2024

Oncology